LEVO-CTS

In patients with LVEF <35% undergoing cardiac surgery does levosimenden compared with placebo reduce the incidence of a composite outcome of: death at day 30; renal replacement therapy at day 30; perioperative myocardial infarct at day 5; and use of mechanical assist device at day 5